Canbi Pharma Tech Limited
1644670-37-0 Iptacopan

1644670-37-0 Iptacopan

CAS:1644670-37-0 MF:C25H30N2O4 MW:422.52 EINECS: MDL No.:MFCD32174282

Send Inquiry
Description

Properties

Appearance Off-white to gray Solid
Boiling point:599.1±50.0 °C
Density 1.25±0.1 g/cm3
storage temp. Store at -20°C
solubility DMSO:50.0(Max Conc. mg/mL);118.34(Max Conc. mM)
pka4.07±0.10

 

Application:

     Complement deposition is often seen in renal biopsy reports of patients with immunoglobulin A (IgA) nephropathy, so some scholars speculate that inhibiting complement can treat some IgA nephropathy patients. Iptacopan (LNP023) is a factor B inhibitor that has complement inhibitory effects. In previous clinical studies, compared to glucocorticoids, its impact on the immune and endocrine systems was relatively small, and the risk of serious adverse events was relatively low. It may be used to treat IgA nephropathy.

 

Synonyms:

Iptacopan

1644670-37-0

LNP023

LNP-023

NVP-LNP023

NVP-LNP023-NX

4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid

Benzoic acid, 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]-

FABHALTA

LNP 023

Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid

4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid

iptacopanum

4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid

Factor B Inhibitor LNP023

GTPL10710

LNP023

 

 

Hot Tags: 1644670-37-0 iptacopan, China 1644670-37-0 iptacopan manufacturers, suppliers, api passwordless authentication api integration, api management platforms, Piracetam, api expense tracking api integration, Sulfaquinoxaline, api artificial intelligence powered api integration

Inquiry
goTop

(0/10)

clearall